Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

CONVERGENT DIAGNOSTICS, LLC

NPI: 1558808204 · ALLEN, TX 75002 · Clinical Medical Laboratory · NPI assigned 01/19/2017

$3.18M
Total Medicaid Paid
378,278
Total Claims
228,486
Beneficiaries
81
Codes Billed
2018-08
First Month
2024-07
Last Month

Provider Details

Authorized OfficialINGRAM, MARC (CEO)
NPI Enumeration Date01/19/2017

Related Entities

Other providers sharing the same authorized official: INGRAM, MARC

ProviderCityStateTotal Paid
KNOXVILLE DERMATOPATHOLOGY LABORATORY LLC PLANO TX $942K
FIRSTPATH LABORATORY SERVICES LLC POMPANO BEACH FL $174K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 1,562 $0.00
2019 3,820 $2K
2020 14,331 $166K
2021 30,215 $305K
2022 148,469 $1.14M
2023 113,423 $1.15M
2024 66,458 $420K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 104,206 21,285 $1.08M
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 6,821 4,657 $301K
88377 1,887 1,468 $196K
88120 2,599 2,046 $172K
87481 25,758 11,431 $168K
88312 4,862 4,098 $150K
87900 9,923 8,052 $149K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 19,053 15,465 $67K
87529 10,820 6,624 $54K
87653 14,601 11,659 $52K
87641 14,460 12,012 $50K
87500 13,319 10,968 $45K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 3,945 3,451 $45K
88305 Level IV - Surgical pathology, gross and microscopic examination 2,540 2,353 $42K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 2,818 2,292 $40K
87563 12,029 9,385 $35K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 10,643 8,148 $35K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 4,968 4,266 $34K
87581 9,593 7,491 $30K
87486 8,696 6,936 $29K
87541 9,034 7,052 $28K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 3,852 2,798 $28K
87631 2,685 2,198 $28K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 8,831 6,780 $28K
87640 6,892 5,424 $23K
87511 9,833 7,636 $23K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 495 457 $22K
87799 1,818 1,647 $20K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 2,457 1,133 $20K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 9,155 6,932 $18K
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 3,927 3,208 $14K
88311 2,241 2,089 $12K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 2,254 1,679 $10K
87482 2,242 2,083 $10K
88104 2,611 2,054 $10K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,586 1,367 $9K
87551 1,282 995 $9K
0500T 2,271 1,527 $9K
87652 2,276 2,005 $9K
88313 272 256 $8K
88304 220 212 $8K
87625 2,644 2,303 $7K
87496 2,068 1,166 $7K
87561 945 804 $7K
87507 268 258 $7K
88142 2,337 1,886 $6K
87582 416 293 $5K
87498 2,135 1,679 $4K
88342 954 834 $4K
87492 846 670 $2K
0853T 252 155 $2K
87556 310 235 $2K
88112 397 337 $2K
88341 492 459 $2K
87497 418 297 $1K
88141 321 225 $1K
87592 430 379 $999.09
87542 390 268 $836.50
88364 310 279 $606.68
87530 66 56 $378.82
87205 397 369 $271.21
88365 311 280 $268.80
88143 199 183 $246.85
87632 69 63 $157.00
87512 56 48 $155.49
81001 572 487 $112.16
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 146 136 $109.27
0831T 21 21 $84.00
88300 62 56 $76.53
87338 109 107 $61.35
0827T 13 12 $56.00
87471 15 15 $53.06
83993 85 85 $33.56
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 64 63 $25.00
81003 80 75 $20.50
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 107 97 $9.94
82270 81 81 $7.49
0756T 19 19 $0.00
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 46 46 $0.00
81007 25 20 $0.00
88160 27 21 $0.00